These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 37516196

  • 21. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ, Hu X, Conti RM, Jena AB, Goldman DP.
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
    Benjamin DJ, Xu A, Lythgoe MP, Prasad V.
    JAMA Netw Open; 2022 Mar 01; 5(3):e222265. PubMed ID: 35289858
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
    Jiang DM, Chan KKW, Jang RW, Booth C, Liu G, Amir E, Mason R, Everest L, Elimova E.
    Cancer Med; 2019 Apr 01; 8(4):1584-1593. PubMed ID: 30848108
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ, Egilman AC, Wallach JD, Ramachandran R, Gupta R, Ross JS.
    JAMA Health Forum; 2022 May 01; 3(5):e221158. PubMed ID: 35977252
    [Abstract] [Full Text] [Related]

  • 31. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
    Goldhaber-Fiebert JD, Cipriano LE.
    Med Decis Making; 2023 May 01; 43(7-8):914-929. PubMed ID: 37698120
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H, Liu K, Pariser A, Pazdur R.
    Clin Cancer Res; 2012 Oct 01; 18(19):5172-8. PubMed ID: 22718862
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD.
    Cochrane Database Syst Rev; 2014 Oct 16; 2014(10):CD005979. PubMed ID: 25318966
    [Abstract] [Full Text] [Related]

  • 36. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M, Naci H, Davis C.
    Milbank Q; 2020 Dec 16; 98(4):1219-1256. PubMed ID: 33021339
    [Abstract] [Full Text] [Related]

  • 37. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
    Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R.
    Ann Oncol; 2017 May 01; 28(5):1111-1116. PubMed ID: 28453694
    [Abstract] [Full Text] [Related]

  • 38. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.
    Ivama-Brummell AM, Marciniuk FL, Wagner AK, Osorio-de-Castro CGS, Vogler S, Mossialos E, Tavares-de-Andrade CL, Naci H.
    Lancet Reg Health Am; 2023 Jun 01; 22():100506. PubMed ID: 37235087
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.